Skip to main content

Table 1 Patient characteristics of the intent-to-treat populationa

From: Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial

Characteristic ASAQ
(n = 184)
AL
(n = 182)
p-value
Sex, n (%)    
   Male 102 (55.4) 98 (53.8) 0.76b
Age, years    
   Mean ± SD 11.94 ± 10.52 11.75 ± 9.17 0.67c
   Range 0.8-65.0 1.2-60.0  
<12 years, n (%) 101 (54.9) 100 (54.9) 0.99b
Weight, kg    
   Mean ± SD 29.55 ± 16.11 31.08 ± 17.34 0.59c
   Range 9.0-89.0 7.6-77.2  
BMI, kg/m2    
   Mean ± SD 14.87 ± 3.11 14.99 ± 3.22 0.58c
   Range 10.0-29.7 9.8-27.4  
Parasite density, asexual forms/μl    
   Geometric mean 32383.9 ± 37362 31713.7 ± 37253 0.716c
   Range 1034-195764 1016-195837  
Gametocyte carriers, n (%) 7 (3.8) 2 (1.1) 0.174d
Blood haemoglobin, g/dL    
   Mean ± SD 10.9 ± 2.3 10.8 ± 2.5 0.85e
   Range 5.8-15.8 5.5-18.2  
  1. aAll randomized patients receiving at least one dose of study drug (patients vomiting twice after receipt of first dose were excluded); bChi2 test; cWilcoxon rank test; dFisher's exact test; eStudent t-test.